Abivax (ABVX) Enterprise Value (2021 - 2025)
Historic Enterprise Value for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to -$168.6 million.
- Abivax's Enterprise Value rose 3906.4% to -$168.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$168.6 million, marking a year-over-year increase of 3906.4%. This contributed to the annual value of -$158.0 million for FY2024, which is 4407.05% up from last year.
- Per Abivax's latest filing, its Enterprise Value stood at -$168.6 million for Q3 2025, which was up 3906.4% from -$73.1 million recorded in Q2 2025.
- In the past 5 years, Abivax's Enterprise Value registered a high of -$27.5 million during Q4 2022, and its lowest value of -$281.0 million during Q4 2023.
- Over the past 5 years, Abivax's median Enterprise Value value was -$163.3 million (recorded in 2024), while the average stood at -$171.7 million.
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 92182.67% in 2023, then surged by 7348.78% in 2025.
- Quarter analysis of 5 years shows Abivax's Enterprise Value stood at -$69.4 million in 2021, then surged by 60.4% to -$27.5 million in 2022, then plummeted by 921.83% to -$281.0 million in 2023, then surged by 43.77% to -$158.0 million in 2024, then decreased by 6.72% to -$168.6 million in 2025.
- Its last three reported values are -$168.6 million in Q3 2025, -$73.1 million for Q2 2025, and -$112.9 million during Q1 2025.